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1Introduction
About 5–10% of breast and/or ovarian cancer cases have 
a hereditary background, mainly dependent on highly 
penetrant mutations in the BRCA1 and BRCA2 genes [1]. 
The reported cumulative breast cancer risk by the age of 
70 is 55–65% for BRCA1 and 45–47% for BRCA2 muta-
tion carriers, while the ovarian cancer risk is 39% for 
BRCA1 and 11–17% for BRCA2 mutation carriers [2, 3]. 
Differences in mutation type and site may at least partially 
impact on cancer risk definition [4, 5].
BRCA1 and BRCA2 gene mutations are typically found 
in 25–30% of the breast cancer families subjected to genetic 
testing [6, 7]. Therefore, the search for germline muta-
tions has often remained negative even in families with 
a Mendelian inheritance pattern for breast and/or ovarian 
cancer [8]. However, recent improvements in DNA 
sequencing technology enabled massively parallel sequenc-
ing of multiple targets, dramatically improving the speed 
and the efficiency of DNA testing. A number of different 
multigene panels have been designed for the analysis of 
hereditary cancer syndrome families, which may include 
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Abstract
The introduction of multigene panel testing for hereditary breast/ovarian cancer 
screening has greatly improved efficiency, speed, and costs. However, its clinical 
utility is still debated, mostly due to the lack of conclusive evidences on the 
impact of newly discovered genetic variants on cancer risk and lack of evidence- 
based guidelines for the clinical management of their carriers. In this pilot 
study, we aimed to test whether a systematic and multiparametric characteriza-
tion of newly discovered mutations could enhance the clinical utility of multigene 
panel sequencing. Out of a pool of 367 breast/ovarian cancer families Sanger- 
sequenced for BRCA1 and BRCA2 gene mutations, we selected a cohort of 20 
BRCA1/2- negative families to be subjected to the BROCA- Cancer Risk Panel 
massive parallel sequencing. As a strategy for the systematic characterization of 
newly discovered genetic variants, we collected blood and cancer tissue samples 
and established lymphoblastoid cell lines from all available individuals in these 
families, to perform segregation analysis, loss- of- heterozygosity and further mo-
lecular studies. We identified loss- of- function mutations in 6 out 20 high- risk 
families, 5 of which occurred on BRCA1, CHEK2 and ATM and are esteemed 
to be risk- relevant. In contrast, a novel RAD50 truncating mutation is most 
likely unrelated to breast cancer. Our data suggest that integrating multigene 
panel testing with a pre- organized, multiparametric characterization of newly 
discovered genetic variants improves the identification of risk- relevant alleles 
impacting on the clinical management of their carriers.
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relatively few and syndrome- oriented target genes, or much 
larger gene sets [9–11]. Similar approaches have now been 
applied to the screening of large cohorts of BRCA1/2 
negative hereditary breast/ovarian cancer families finding 
mutations in non- BRCA1/2 genes in 4–11% of the cases, 
depending on the features of the patients cohorts and/or 
on the size of the multigene panel [10–15]. In these stud-
ies, loss- of- function mutations were identified either in 
known, syndrome- related highly penetrant genes (i.e., TP53 
and PTEN) or in a number of rarely mutated targets, 
whose impact on breast/ovarian cancer risk is largely 
undefined [11, 15, 16]. Accordingly, the introduction of 
Next generation sequencing (NGS) multigene panels for 
diagnostic purposes is still debated, since their clinical 
utility is often limited by scant information on the cancer 
risk conferred by rare genetic variants and lack of evidence- 
based guidelines for the clinical management of their 
carriers [16]. Large case–control studies have recently 
confirmed PALB2 as a high- risk breast cancer gene, but 
they still reached conflicting results on ATM and CHEK2 
and rejected the role of many other genes, such as those 
of the MRN complex [17, 18].
Defining the impact of gene mutations on cancer risk 
might be a very difficult task especially for rarely mutated 
genes, hit by different mutation types in different sites. 
Nonetheless, aiming at this target is mandatory for a cor-
rect application of multigene panel sequencing in the 
clinical settings. To focus on this key question, we reasoned 
that integrating gene panel sequencing with the systematic 
use of prediction tools, cosegregation and loss of heterozy-
gosity (LOH) analysis, together with the availability of 
patient- derived lymphoblastoid cell lines (LCL) for func-
tional studies could provide significant hints on the impact 
of newly discovered gene mutations on cancer risk, improv-
ing the clinical utility of NGS screenings. In this pilot 
study, we report on the application of this strategy to a 
cohort of twenty breast/ovarian cancer families with a 
moderate- to- high probability to be mutation carriers.
Materials and Methods
Family recruitment
About 367 breast and/or ovarian cancer families were 
enrolled at the Hereditary Tumors section of the Policlinico 
Umberto I, University La Sapienza, and probands have 
been subjected to BRCA1/2 mutation screening (Table S1) 
[19, 20]. Out of the BRCA1/2 negative group, we selected 
20 (BRCAX) families characterized by high probability to 
be mutation carriers, as described in the Results section. 
DNA samples from peripheral blood or cancer tissues, were 
subjected to multigene panel NGS or Sanger sequencing, 
respectively. Lymphoblastoid cell lines (LCL) were generated 
from probands and available relatives, using a standard 
protocol [21]. A careful pretest counseling has been offered 
to all probands and their relatives to obtain a truly informed 
consent. All investigations were conducted according to 
the principles outlined in the declaration of Helsinki.
BRCA1/2 mutation screening
Genomic DNA was extracted from peripheral blood sam-
ples using a commercial kit (QIAamp Blood Kit, Qiagen, 
Valencia, CA). The entire coding sequence and all intron/
exon boundaries of BRCA1 and BRCA2 were screened 
by direct sequencing using an ABI PRISM DyeDeoxy 
Terminator Cycle Sequencing Kit and an ABI 3130XL 
Genetic Analyzer (Applied Biosystems, Warrington, UK) 
as previously described [19, 20]. Sequences were compared 
against BRCA1 and BRCA2 reference sequences (GenBank 
NM_007294.3 and NM_000059.3; additional GenBank 
reference sequence were as follows: ATM, NM_000051.3; 
CHEK2, NM_007194.3; RAD50, NM_005732.3). DNA 
mutation nomenclature followed current guidelines of the 
Human Genome Variation Society (http://www.hgvs.org/
rec.html). BRCA1/2 genomic rearrangements were searched 
for by the Multiple- Ligation- dependent- Probe- Amplification 
(MLPA) methodology according to the manufacturer’s 
instructions (MRC–Holland, Amsterdam, the Netherlands) 
and as described [22].
Next generation sequencing
NGS and data analysis have been performed on service 
at the University of Washington- Seattle using the BROCA- 
Cancer Risk panel (http://tests.labmed.washington.edu/
BROCA), an approach of genomic capture and massively 
parallel sequencing of 41 putative breast/ovarian cancer 
genes, according to Walsh et al. [12]. All described vari-
ants were subsequently validated in our laboratory by 
Sanger sequencing.
RNA extraction and RT- PCR
LCLs were untreated and treated with cycloheximide (CHX, 
100 μg/mL) for 4 h in order to block non- sense mediated 
decay. Total RNA extraction was performed using TRI 
Reagent® (Sigma- Aldrich, Co.) according to the manu-
facturer’s instructions. 1 μg of the RNA was retro- 
transcribed and PCR amplified as described [23] (primer 
sequences are available on request).
Tumor- tissue histology
For each paraffin- embedded tumor, six 10- μm paraffin 
slides were used for genomic- DNA isolation [24, 25] and 
3© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
NGS Screening and Risk- Relevant VariantsA. Coppa et al.
a hematoxylin- eosin–stained slide was used for histopatho-
logical examination.
Results
On a sample of 266 breast cancer (BC) and 101 breast/
ovarian cancer families (BOC) Sanger sequenced for 
BRCA1/2 genes, 97 (26%) carried deleterious mutations 
(Table S1). In line with the literature [1, 7], the mutational 
rate in BC families was dramatically lower (13%) compared 
to BOC families (60%), suggesting that a high percentage 
of them remains without a conclusive genetic diagnosis.
To extend the possibility to identify mutations responsible 
for breast cancer inheritance, we applied multigene panel 
sequencing to a small cohort of hereditary BC/BOC families, 
which shared the following criteria: (1) being negative for 
BRCA1/2 truncating or missense deleterious mutation, after 
standard Sanger sequencing; being willing to provide; (2) 
blood and DNA samples from affected and unaffected 
individuals to establish LCLs and to perform segregation 
analysis; and (3) tumor tissue from at least one affected 
individual to perform LOH studies. In order to provide a 
proof- of- concept that this strategy may enhance the iden-
tification of mutations impacting on cancer risk definition 
and clinical management of the carrier families, we limited 
the cohort to 20 families having a clear dominant inherit-
ance pattern and/or a high BRCAPro score. Consistent with 
the much lower level of BRCA1/2 mutation rate in BC 
families, 17 out of 20 were BC families and only three 
were BOC families (Table 1). Of note, 11 out of the 20 
probands showed a very high BRCAPro score (between 
97% and 75%) and 6 had a BRCAPro score between 50% 
and 67%. We also included three families with a BRCAPro 
<50% that showed co- occurrence of OC and BC, or the 
presence of bilateral BC before age 38 years in the proband, 
plus significant family history (Table 1; Table S2).
By this approach, we identified loss- of- function muta-
tions in 6/20 (30%) probands, five of which occurred on 
BRCA1, CHEK2, and ATM and are esteemed to be risk- 
relevant according to our studies (Table 2, Fig. 1), while 
a novel RAD50 truncating mutation is most likely unrelated 
to breast cancer. Interestingly, all these mutations occurred 
in families with a very high BRCAPro score (75–97%).
Despite previous BRCA1/2 testing, the NGS approach 
identified two novel BRCA1 deleterious mutations. One 
is a BRCA1/NBR2 rearrangement (NBR2del EX1_BRCA1 
delEX1- 2). PCR amplification of genomic DNA from the 
BR409 proband resulted in an aberrant fragment of 
approximately 670 bp (Fig. 2A), whose direct sequencing 
confirmed the putative breakpoints. As reported in 
Figure 2, loss of NBR2 exon1 and BRCA1 exons 1 and 
2 possibly originated from an erroneous homologous 
recombination process between two AluY motifs, located 
at chr17:41279963 and at chr17:41273315, respectively 
(Fig. 2B). We detected this mutation in a 38- year- old 
woman (BR409), with bilateral breast cancer at age 30 
and 32, belonging to a very high- risk family (BRCAPro 
91%) (Fig. 1). As expected, this mutation cosegregates 
with the disease (Table 2).
The second BRCA1 mutation is a synonymous variant 
on the last codon of exon 17 (c.5073A>T; p.Thr1691=) 
already identified, but not considered relevant, at the time 
of the first Sanger sequencing. The NNSPLICE prediction 
tool (http://fruitfly.org:9005/seq_tools/splice.html) sug-
gested it could cause an alternative splicing with skipping 
of exon 17, and exon 16–18 out- of- frame joining. The 
functional consequences on this mutation was ascertained 
by RT- PCR and sequencing analysis of the transcripts in 
LCLs, which identified the wild type form (Fig. 3A, frag-
ment C) and the predicted aberrant transcript (Fig. 3A, 
fragment D) skipping exon 17 and carrying a premature 
stop codon at residue 1672 (p.Met1663 fs). Moreover, 
we observed an additional transcript (Fig. 3A, fragment 
A), incorporating a 153 bp sequence of intron 17 (pre-
ceding a typical GT 5′- splice signal) that created a stop 
codon at residue 1706 (p.Asp1692fs). A further 570 bp 
band (Fig. 3A, fragment B), instead, proved to be a het-
eroduplex rather than a specific splicing product (Fig. 3B). 
All the aberrant transcripts were detected in the BR404 
proband, but not in control LCLs and they increased 
with cycloheximide (CHX) treatment, suggesting they all 
suffer a non- sense mediated decay (Fig. 3A). We identi-
fied the c.5073A>T (p.Thr1691=) variant in a woman 
(BR404, BRCAPro 82%) with bilateral breast cancer at 
age 73 (Fig. 1). Also in this case, the mutation cosegre-
gated with the diseases in 100% of the cases (Table 2). 
Moreover, we showed LOH for the mutant allele in the 
tumor tissue of the proband and both her daughters 
(Fig. 3D; Table S3). These data strongly suggest that the 
Table 1. Clinical characteristics of BRCAX Probands.
No. of cases (%)
Proband cancer history 20
Unilateral breast 9 45
Bilateral breast 10 50
Ovarian 1 5
Second primary malignancy 2 10
Proband age of cancer onset 20
25–35 4 20
36–50 14 70
>50 2 10
BRCApro- 5 score (%) 20
>75 11 55
50–75 6 30
<50 3 15
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BRCA1/NBR2 rearrangement and BRCA1 c.5073A>T 
(p.Thr1691=) are new loss- of- function and cancer risk- 
relevant mutations.
Two protein- truncating variants occurred on the ATM 
gene. The ATM exon 7 c.824delT mutation resulting in 
a premature termination at codon 275 (p.Leu275Ter) 
occurred in the BR208 proband (BRCAPro 82%) who was 
diagnosed with breast cancer at age 40 (Fig. 1). This muta-
tion cosegregated with the disease in two family members 
affected with early onset breast cancer, but not in an elderly 
Table 2. Mutations identified by NGS.
Family ID Mutation
BRCAPro
Segregation
Total
Healthy Affected
% C NC C NC
BR409 BRCA1/NBR2 NBR2delEX1_BRCA1delEX1- 2 91 0 3 2 0 5
BR404 BRCA1 c.5073A>T (p.Thr1691=) 75 0 3 3 0 6
BR225 ATM c.8833_8834delCT (p.Leu2945 fs) 91 1 0 4 0 5
BR208 ATM c.824delT (p.Leu275Ter) 82 0 3 2 2 7
BR501 CHEK2 c.1232G>A (p.Trp411Ter) 94 4 1 3 1 9
BR17 RAD50 c.326_329delCAGA (p.Thr109 fs) 97 5 4 1 2 12
C, carrier; NC, no carrier.
Figure 1. Pedigrees of the six families with germline mutations identified by NGS. Probands are indicated with an arrow. Tested family members are 
marked with “+” for mutation carriers and “−” for wild- type. Rel1, Rel2: LOH tested family members. Cancer type and age at diagnosis are reported 
and described as: BC, breast cancer; bil BC, bilateral breast cancer; OC, ovarian cancer; MB, male breast; PrC, prostatic cancer; Unknown cancer; 
Neurob, neuroblastoma cancer; NHL, non- Hodgkin lymphoma; Thyr, Thyroid; KC, Kidney cancer; Mel, melanoma; CNS, central nervous system 
cancer; GC, gastric cancer; CC, colon cancer; Endo, endometrial cancer.
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BC case, four unaffected relatives and one melanoma case 
(Table 2). LOH analysis showed maintenance of a heterozy-
gous state of the ATM alleles in normal, preneoplastic 
and neoplastic tissue from the proband (Table S3).
The ATM exon 61 c.8833_8834delCT mutation intro-
duced a stop codon at position 2954 (p.Leu2945fs). It 
occurred in the BR225 proband (BRCAPro 91%) affected 
with breast cancer at age 42 (Fig. 1). This mutation coseg-
regated with the disease in three BC patients (including 
one male) and one colorectal cancer patients (Table 2). 
Also in this case, LOH analysis showed maintenance of 
a heterozygous state, in all tissues examined (Table S3). 
These results were consistent with a risk- relevant role of 
ATM mutations in both families.
The CHEK2 nonsense c.1232G>A mutation on exon 
11 resulted in a premature protein termination at codon 
411 (p.Trp411Ter) predicted to disrupt protein function 
and occurred in the BR501 proband (BRCAPro 94%), 
affected with an early onset breast cancer at age 25 (Fig. 1). 
Extensive segregation analysis in nine individuals of the 
family indicated the mutation segregated with most breast 
cancer cases (three out four) (Table 2). Moreover, we 
showed LOH for the c.1232G>A mutation in the tumor 
tissue (Table S3), supporting a risk- relevant role for this 
mutation.
The novel RAD50 frameshift c.326_329delCAGA muta-
tion in the exon 3 introduced a stop codon at position 
128 (p.Thr109fs), at the level of the ATPaseN domain, 
which predicts a very strong impact on the function of 
the RAD50- MRE11 complex [26]. This mutation occurred 
in the BR17 proband (BRCAPro 97%), who developed 
bilateral breast and thyroid cancer at 49, 56, and 58 years, 
respectively (Fig. 1). Nonetheless, segregation analysis, 
performed in 12 individuals did not support a critical 
role of this mutation, since it did not segregate in the 
other two breast cancer cases (one of which bilateral, at 
44) (Table 2).
Discussion
Recently, the landscape of genetic risk evaluation for breast/
ovarian cancer expanded due to the introduction of the 
NGS technology, which has greatly simplified the search 
for genetic alterations in targets other than BRCA1/2. 
Many different genes were shown to be mutated in breast/
ovarian cancer cohorts, being PALB2, ATM, and CHEK2 
the most frequent [10–14, 27]. However, the clinical utility 
of these studies is still controversial since even large case–
control studies failed to firmly establish an increased risk 
for breast and/or ovarian cancer associated with many of 
the mutated genes [16].
In this pilot study, we reported that association of NGS 
screenings with the systematic use of prediction tools, 
cosegregation and LOH analysis and establishment 
Figure 2. BRCA1/NBR2 rearrangement identified in the BR409 family. (A) Gel image of PCR products. PCR amplification of the genomic region 
spanning the BRCA1/NBR2 rearrangement resulted in a fragment of approximately 670 bp present only in the proband BR409. (B) Schematic 
representation and electropherogram showing the NBR2 exon1 and BRCA1 exons 1 and 2 deletion. The variant arose from an erroneous homologous 
recombination process between two AluY motifs, localized at chr17:41279963 and at chr17:41273315, respectively, and it involved a perfectly 
repeated stretch of 20 bp. MK, marker; NT, no template; 409 proband DNA, 627, 626 healthy individual DNA.
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patient- derived LCL for functional studies improves the 
identification of risk- relevant gene mutations. A similar 
approach had been previously used to establish the clinical 
significance of uncharacterized BRCA1/2 missense muta-
tions [28]. Indeed, the information gathered by this 
approach influenced the choice for the appropriate risk- 
reducing strategy for 5/6 families, in which loss- of- function 
mutations have been detected.
This was rather straightforward for two of them, which 
are novel BRCA1 disease causing mutations, falling into 
class V, according to Plon et al. [29]. Indeed, one is a 
novel BRCA1/NBR2 rearrangement, which may lead to 
lack of BRCA1 transcription, as described for previously 
reported genomic rearrangements [30, 31]. The second 
is a novel BRCA1 synonymous variant (c.5073A>T; 
p.Thr1691=). Our studies on LCL were crucial to dem-
onstrate it gives rise to aberrant alternative transcripts 
that undergo nonsense- mediated decay and code for 
truncated proteins. Since, similar outcomes were previ-
ously reported for the c.5074+1G>T variant affecting the 
consensus GT splicing signal in intron 17 [32], our data 
reveal that the c.5073A>T substitution impairs a strong 
splicing enhancer. The segregation pattern of both muta-
tions and LOH analysis further support the disease- causing 
role of both BRCA1 mutations.
The two ATM protein- truncating mutations we identi-
fied for the first time in breast cancer families, had already 
been reported as either homozygous or compound het-
erozygous alterations in Ataxia- Telangiectasia patients [33, 
34], but their impact on cancer risk was not previously 
described. These mutations segregate in most siblings 
affected with breast and/or other types of cancer. 
Interestingly, we observed no LOH for ATM variants, in 
line with the hypothesis that one mutant ATM allele may 
be sufficient to promote tumor initiation [35, 36]. 
Importantly, both ATM mutations were also picked up 
Figure 3. BRCA1 c.5073A>T (p.Thr1691=) identified in the BR404 family. (A) PCR amplification of the alternative transcripts in patient 404 mRNA 
from LCL exposed or non- exposed to cycloheximide (CHX): (A) 604 bp aberrant fragment; (B) 570 bp aberrant fragment; (C) wt transcript fragment 
and (D) 363 bp aberrant fragment. (B) Melting and reannealing PCR fragments at rising temperatures (80° and 85°C), allow disappearance of band 
B, which indicates it is a heteroduplex. (C) Schematic representation and electropherograms of the excised bands showing the presence of a transcript 
lacking exon17 and of an aberrant transcript retaining a 153 bp fragment of intron 17. (D) Electropherograms of DNA obtained from the blood and 
cancer tissues of proband and her daughters showing LOH with conservation of the c.5073A>T (p.Thr1691=) allele in all cancer tissues (Table S3). 
MK, marker; NT, no template; 225 control LCL; 404 proband LCL; P, B, Proband blood sample; P, BC, Proband breast cancer tissue; Rel1, OC, Relative 
1 ovarian cancer tissue; Rel2, OC, Relative 2 ovarian cancer tissue.
7© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
NGS Screening and Risk- Relevant VariantsA. Coppa et al.
by the p53 mitotic centrosomal localization test, indicating 
they are functionally impaired in governing p53 centro-
somal localization [37]. Overall, our data strongly support 
the role of these ATM mutations in cancer development, 
in these families.
The novel c.1232G>A is a truncating and function 
disrupting mutation of the CHEK2 gene, identified in an 
early onset breast cancer proband. The high number of 
breast cancers observed in this family, cosegregation of 
the variant with the disease and its LOH in the breast 
cancer tissue, strongly suggest this is a breast cancer pre-
disposing allele.
It is worth mentioning that, in principle, the role of 
mutant ATM and CHEK2 as breast cancer genes is still 
debated. However, many studies and a large meta- analysis 
agree that ATM mutations confer a moderate breast cancer 
risk [36, 38, 39] although there might be differences 
between truncating versus missense mutations [40]. 
Moreover, a specific missense allele (c.7271T>G) was 
reported to be associated even with high breast cancer 
risk [41]. In a similar way, the reported breast cancer 
risk for CHEK2 mutations varies largely. The cumulative 
breast cancer risk conferred by the 1100delC CHEK2 vari-
ant is 37% at 70 years [42]. Association studies on four 
different CHEK2 variants, indicated a breast cancer risk 
of 20–44% and 9–12% for truncating mutations and mis-
sense mutation carriers, respectively, largely depending on 
their family history [43]. A recent case–control study on 
a large cohort of patients subjected to multigene panel 
testing further suggest that ATM and CHEK2 are associ-
ated with moderate breast cancer risk [18], providing 
support to NCCN recommendations for an annual mag-
netic resonance screening of these mutation carriers, start-
ing at age 40 [44]. Based on our observations and on 
the knowledge that other genes, such as PALB2, have 
been recently re- classified from moderate to high- 
penetrance BC susceptibility gene [45], we suggest that 
extreme caution is required in defining ATM- or CHEK2- 
dependent cancer risk, and that at least extensive segrega-
tion analysis and LOH studies should be performed for 
each mutation, in order to more appropriately define the 
clinical utility of mutation detection for those genes.
Interestingly, the novel c.326_329delCAGA RAD50 muta-
tion identified in the BR17 family with a very high BRCAPro 
score (97%) exemplifies the challenges in transferring 
genetic data into clinical management deriving from mul-
tigene panel sequencing, and further contribute to support 
the efficacy of our strategy. Indeed, while this protein- 
truncating mutation predicts loss- of- function of the 
RAD50- MRE11 complex [26], it did not cosegregate with 
breast cancer, suggesting it is unlikely to be the risk- 
relevant allele in the BR17 family, where additional genetic 
alterations might be responsible for cancer inheritance. 
Importantly, large case–control studies have also indicated 
lack of significant association between MRN complex gene 
mutations and breast cancer risk [17, 18].
Although uneasy to be performed on large scale and 
in non- research oriented environment, our proposed 
approach identified risk- relevant mutations in 25% of the 
analyzed families. Excluding the two BRCA1 mutations, 
we identified risk- relevant mutations in non- BRCA1/2 
genes in 17% of the families. Therefore, the combination 
of multigene panel sequencing with extended and mul-
tiparametric characterization of the discovered mutations, 
eventually restricted to families with high probability of 
being mutation carriers, stands as very useful approach 
to increase the clinical utility of NGS screening for inher-
ited breast/ovarian cancer.
Finally, we cannot overlook that a consistent number 
of high- risk families still remained without satisfying 
answers despite multigene panel sequencing, in our and 
other’s studies [13, 46]. The overall strategy depicted here 
could be further exploited to identify risk- relevant muta-
tions in these families by additional mutation screenings 
such as whole exome sequencing and/or RNAseq.
In conclusion, we have shown that integrating the sys-
tematic use of cosegregation analysis, LOH and functional 
studies performed on LCL with multigene panel sequencing 
may improve its clinical utility and the clinical manage-
ment of the mutation carriers.
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